Telomir Pharmaceuticals Secures Global Rights to Telomir-1
New York, Tuesday, 21 October 2025.
Telomir Pharmaceuticals signed a binding LOI for global rights to Telomir-1, positioning it for market expansion with potential $5 million shareholder contributions and strategic partnerships.
Overview of the Agreement
On October 21, 2025, Telomir Pharmaceuticals (NASDAQ: TELO) announced the execution of a binding Letter of Intent (LOI) to acquire TELI Pharmaceuticals, securing worldwide rights to its lead investigational therapy, Telomir-1. This strategic move is set to align Telomir’s U.S. rights with TELI’s ex-U.S. intellectual property portfolio, which encompasses regions including Europe, Canada, and Asia, among others [1][2].
Financial and Strategic Implications
The agreement includes up to $5 million in potential shareholder contributions from TELI, structured as $1 million at closing, $2 million upon FDA IND acceptance, and $2 million upon the initiation of a Phase 1/2 study [3]. These contributions are designed to bolster Telomir’s financial strength as it seeks to expand its market reach and establish strategic partnerships across the globe [4].
Market Context and Potential
The pharmaceutical industry is experiencing rapid growth, with global oncology spending projected to reach approximately $409 billion by 2028, up from $223 billion in 2023 [1]. This trend underscores the significance of Telomir’s expansion into international markets, particularly as the demand for innovative cancer therapies like Telomir-1 rises. Additionally, the age-related macular degeneration drug market is expected to grow from $10.8 billion in 2023 to $18 billion by 2030, highlighting further opportunities for Telomir [5].
Strategic Vision and Future Prospects
Telomir’s CEO, Erez Aminov, emphasized that securing global rights transforms Telomir-1 from a U.S.-focused asset into a global platform. This alignment aims to streamline development pathways and enhance partnership opportunities in key markets. The transaction is not contingent on the receipt of milestone payments, ensuring a robust framework for international collaboration and value growth [2][4].